Updates on the biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity von Mantini, G., Papini, F., Capula, M., Randazzo, O., Gregori, A., Liu, D., Peter, G., Frampton, A., Garajova, I., Giovannetti, E.

Volltext

Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not recei... von Tavolari, S., Deserti, M., Vasuri, F., Curti, S., Palloni, A., Pinna, A.D., Cescon, M., Frega, G., De Lorenzo, S., Barbera, M.A., Garajova, I., Ricciardiello, L., Malvi, D., D'Errico-Grigioni, A., Pantaleo, M.A., Brandi, G.

Volltext

Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation von GARAJOVÁ, I., NEPOTI, G., PARAGONA, M., BRANDI, G., BIASCO, G.

Volltext

Whole-exome sequencing analysis identifies recurrent mutation rate in BAP1 gene in intrahepatic cholangiocarcinoma patients exposed to asbestos von Brandi, G., Deserti, M., Astolfi, A., Indio, V., Farioli, A., Mattioli, S., Palloni, A., De Lorenzo, S., Garajova, I., Vasuri, F., Pinna, A.D., Cescon, M., Tavolari, S.

Volltext

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey von Orsi, G., Di Marco, M., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I.G., Garajova, I., Tortora, G., Rodriquenz, M.G., Bittoni, A., Penzo, E., De Lorenzo, S., Peretti, U., Paratore, C., Bernardini, I., Mosconi, S., Spallanzani, A., Macchini, M., Tamburini, E., Bencardino, K., Giommoni, E., Scartozzi, M., Forti, L., Valente, M.M., Militello, A.M., Cascinu, S., Milella, M., Reni, M.

Volltext

Significant overexpression of Hsp110 gene during colorectal cancer progression von SLABY, O, SOBKOVA, K, SMERDOVA, T, KNOFLICKOVA, D, VYZULA, R, SVOBODA, M, GARAJOVA, I, FABIAN, P, HRSTKA, R, NENUTIL, R, SACHLOVA, M, KOCAKOVA, I, MICHALEK, J

Volltext

1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study von Orsi, G., Notini, G., Lucin, E., Chiaravalli, M., Di Marco, M.C., Giommoni, E., Bozzarelli, S., Bianco, R., Pala, L., Macchini, M., Carconi, C., Leta, L.C., Tortora, G., Morelli, C., Spallanzani, A., Garajova, I., Scartozzi, M., Messineo, L., Falconi, M., Reni, M.

Volltext

189P The synergic effect of metformin and atezolizumab/bevacizumab in diabetic HCC patients: A retrospective study from ARTE multicentric Italian dataset von Dalbeni, A., Auriemma, A., Stefanini, B., Vivaldi, C., Federico, P., Palloni, A., Soldà, C., Garajova, I., Tamberi, S., De Lorenzo, S., Piscaglia, F., Masi, G., Leonardi, S., Brandi, G., Daniele, B., Trevisani, F., Marra, F., Tovoli, F., Milella, M., Sacerdoti, D.

Volltext

142P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study von Rimini, M., Persano, M., Foti, S., Fornaro, L., Lonardi, S., Niger, M., Tamburini, E., Lavacchi, D., Rapposelli, I.G., Martinelli, E., Garajova, I., Simionato, F., Camera, S., Rossari, F., Amadeo, E., Vitiello, F., Cascinu, S., Rimassa, L., Antonuzzo, L., Casadei Gardini, A.

Volltext

1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations von Milella, M., Orsi, G., Palloni, A., Salvatore, L., Procaccio, L., Noventa, S., Bozzarelli, S., Garajova, I., Vasile, E., Giordano, G., Macchini, M., Cavaliere, A., Gaule, M., Lonardi, S., Di Marco, M.C., Tortora, G., Sperduti, I., Reni, M.

Volltext

The impact of etiology on patterns of progression of advanced HCC von Stefanini, B., Piscaglia, F., Dalbeni, A., Vivaldi, C., Federico, P., Palloni, A., Soldà, C., Garajova, I., Ielasi, L., De Lorenzo, S., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Trevisani, F., Svegliati-Baroni, G., Campani, C., Chen, R., Tovoli, F.

Volltext

Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease? von Tovoli, F., Chen, R., Vivaldi, C., Federico, P., Palloni, A., Natola, L.A., Soldà, C., Stefanini, B., Garajova, I., Ielasi, L., De Lorenzo, S., Granito, A., Monaco, G., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Dalbeni, A., Lani, L., Svegliati-Baroni, G., Campani, C., Piscaglia, F.

Volltext

The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset von Dalbeni, A., Vicardi, M., Natola, L.A., Auriemma, A., Stefanini, B., Vivaldi, C., Federico, P., Palloni, A., Soldà, C., Lani, L., Garajova, I., Tamberi, S., De Lorenzo, S., Piscaglia, F., Milella, M., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Trevisani, F., Svegliati-Baroni, G., Marra, F., Tovoli, F., Sacerdoti, D.

Volltext

Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab von Tovoli, F., Boe, M., Vivaldi, C., Federico, P., Palloni, A., Dalbeni, A., Soldà, C., Stefanini, B., Garajova, I., Ielasi, L., De Lorenzo, S., Granito, A., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Auriemma, A., Lani, L., Svegliati-Baroni, G., Campani, C., Piscaglia, F.

Volltext

Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study von Tovoli, F., Vivaldi, C., Federico, P., Stefanini, B., Palloni, A., Dalbeni, A., Soldà, C., Lani, L., Garajova, I., Tamberi, S., De Lorenzo, S., Granito, A., Pallotta, D.P., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Sacerdoti, D., Svegliati-Baroni, G., Campani, C., Pellegrini, E., Piscaglia, F.

Volltext

Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma von Tovoli, F., Franceschini, E., Vivaldi, C., Federico, P., Palloni, A., Dalbeni, A., Soldà, C., Stefanini, B., Garajova, I., Ielasi, L., De Lorenzo, S., Granito, A., Chen, R., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Sacerdoti, D., Lani, L., Svegliati-Baroni, G., Campani, C., Piscaglia, F.

Volltext

Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma von Tovoli, F., Dadduzio, V., De Lorenzo, S., Rimassa, L., Masi, G., Iavarone, M., Marra, F., Garajova, I., Brizzi, M.P., Daniele, B., Trevisani, F., Messina, C., Clemente, F. Di, Pini, S., Cabibbo, G., Granito, A., Rizzato, M.D., Zagonel, V., Brandi, G., Pressiani, T., Federico, P., Vivaldi, C., Bergna, I., Campani, C., Piscaglia, F.

Volltext

Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic c... von Barbera, M.A., Frega, G., Palloni, A., Abbati, F., Biasco, G., Garajova, I.

Volltext

The overall survival of patients affected by metastatic colorectal cancer before and after “monoclonal antibodies era”: a monocentric retrospective study von Abbati, F., Barbera, M.A., Palloni, A., Frega, G., Biasco, G., Garajova, I.

Volltext

Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer von Palloni, A., Barbera, M.A., Frega, G., Abbati, F., Biasco, G., Garajova, I.

Volltext